NASDAQ:INGNInogen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $36.27 +0.41 (+1.14 %) (As of 07/6/2020 04:00 PM ET) Add Compare Share Today's Range$35.88Now: $36.27▼$36.9950-Day Range$32.85MA: $36.37▼$41.2352-Week Range$31.21Now: $36.27▼$76.89Volume184,100 shsAverage Volume401,045 shsMarket Capitalization$799.68 millionP/E Ratio57.57Dividend YieldN/ABeta0.79 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.Read More Beat the Market (BTM) Rank™ 3.1 Analyst's Opinion Consensus RatingInogen has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 2 buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.80, Inogen has a potential upside of 67.6% from its current price of $36.27.Amount of Analyst CoverageInogen has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesInogen has received 371 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInogen has received 246 “underperform” votes. (Add your “underperform” vote.)Community SentimentInogen has received 60.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote “Outperform” if you believe INGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInogen does not currently pay a dividend.Dividend GrowthInogen does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.83% of the stock of Inogen is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inogen are expected to grow in the coming year, from ($0.07) to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inogen is 57.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Inogen is 57.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.37.Price to Book Value per Share RatioInogen has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.34 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INGN Previous Symbol CUSIPN/A CIK1294133 Webwww.inogen.com Phone805-562-0500Debt Debt-to-Equity Ratio0.03 Current Ratio5.43 Quick Ratio4.75Price-To-Earnings Trailing P/E Ratio57.57 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$361.94 million Price / Sales2.21 Cash Flow$1.71 per share Price / Cash Flow21.18 Book Value$15.67 per share Price / Book2.31Profitability EPS (Most Recent Fiscal Year)$1.07 Net Income$20.95 million Net Margins3.90% Return on Equity4.93% Return on Assets3.84%Miscellaneous Employees1,020 Outstanding Shares22,048,000Market Cap$799.68 million Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:INGN Rates by TradingView Receive INGN News and Ratings via Email Sign-up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Inogen (NASDAQ:INGN) Frequently Asked Questions How has Inogen's stock been impacted by COVID-19 (Coronavirus)? Inogen's stock was trading at $40.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INGN shares have decreased by 10.7% and is now trading at $36.27. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Inogen? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen. When is Inogen's next earnings date? Inogen is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Inogen. How were Inogen's earnings last quarter? Inogen Inc (NASDAQ:INGN) posted its quarterly earnings data on Tuesday, May, 5th. The medical technology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The medical technology company had revenue of $88.49 million for the quarter, compared to analyst estimates of $82.33 million. Inogen had a return on equity of 4.93% and a net margin of 3.90%. Inogen's revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.24 earnings per share. View Inogen's earnings history. What price target have analysts set for INGN? 7 analysts have issued twelve-month price targets for Inogen's stock. Their forecasts range from $45.00 to $80.00. On average, they expect Inogen's stock price to reach $60.80 in the next year. This suggests a possible upside of 67.6% from the stock's current price. View analysts' price targets for Inogen. Has Inogen been receiving favorable news coverage? News headlines about INGN stock have been trending negative this week, according to InfoTrie. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inogen earned a news impact score of -2.1 on InfoTrie's scale. They also assigned headlines about the medical technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Inogen. Are investors shorting Inogen? Inogen saw a drop in short interest in June. As of June 30th, there was short interest totaling 2,560,000 shares, a drop of 9.5% from the June 15th total of 2,830,000 shares. Based on an average daily trading volume, of 391,100 shares, the days-to-cover ratio is currently 6.5 days. Approximately 14.0% of the company's stock are sold short. View Inogen's Current Options Chain. Who are some of Inogen's key competitors? Some companies that are related to Inogen include Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), COLLPLANT HOLDI/S (CLGN), ConforMIS (CFMS), Allied Healthcare Products (AHPI), Histogenics (HSGX), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Ocugen (OCGN), NanoVibronix (NAOV) and Bionik Laboratories (BNKL). View all competitors. What other stocks do shareholders of Inogen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), First Solar (FSLR), Netflix (NFLX), Intel (INTC) and Advanced Micro Devices (AMD). Who are Inogen's key executives? Inogen's management team includes the following people: Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)Mr. Bart Sanford, Exec. VP of Operations (Age 53)Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40) What is Inogen's stock symbol? Inogen trades on the NASDAQ under the ticker symbol "INGN." How do I buy shares of Inogen? Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Inogen's stock price today? One share of INGN stock can currently be purchased for approximately $36.27. How big of a company is Inogen? Inogen has a market capitalization of $799.68 million and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe. What is Inogen's official website? The official website for Inogen is www.inogen.com. How can I contact Inogen? Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
